SCHEMBL18038944

SCHEMBL18038944

O=C(Cn1cc(S(=O)(=O)N2CCCC2)ccc1=O)c1ccc(-c2ccccc2Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 2/20 0.51
▸ AKR1C1 Q04828 1/20 0.51
▸ ALDH1A1 P00352 4/20 0.48
▸ LMNA P02545 3/20 0.48
▸ POLB P06746 3/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.48
▸ PKM P14618 2/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ TSHR P16473 2/20 0.43
▸ USP2 O75604 2/20 0.43
▸ HTT P42858 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ GAA P10253 1/20 0.41
▸ AGTR1 P30556 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18038963 0.89 ALDH1A1 (0.48) ALDH1A1LMNAPOLBSMN1; SMN2NPSR1
SCHEMBL18038948 0.89 ALDH1A1 (0.60) ALDH1A1LMNAPOLBSMN1; SMN2NPSR1
SCHEMBL18038954 0.88 L3MBTL1 (0.56) ALDH1A1LMNAPOLBSMN1; SMN2NPSR1
SCHEMBL18038989 0.88 L3MBTL1 (0.56) ALDH1A1LMNAPOLBSMN1; SMN2NPSR1
SCHEMBL18038959 0.88 L3MBTL1 (0.56) ALDH1A1LMNAPOLBSMN1; SMN2NPSR1
SCHEMBL21749675 0.88 L3MBTL1 (0.50) AKR1C3AKR1C1ALDH1A1LMNAPOLB
SCHEMBL18038949 0.87 GAA (0.50) ALDH1A1LMNAPOLBL3MBTL1HTT
SCHEMBL18039005 0.87 L3MBTL1 (0.47) ALDH1A1LMNAPOLBSMN1; SMN2NPSR1
SCHEMBL18038995 0.86 ALDH1A1 (0.49) ALDH1A1LMNAPOLBL3MBTL1HTT
SCHEMBL18038961 0.86 ALDH1A1 (0.48) ALDH1A1LMNAPOLBSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11311523-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2022-04-26 — — US disclosed
EP-3692992-A1 METHOD OF SCREENING DOCK1-SELECTIVE INHIBITORS FOR CANCER TREATMENT Kyushu University National University Corporation (JP) 2020-08-12 — — EP disclosed
EP-3263133-B1 PYRIDINONE COMPOUND AND USE THEREOF UNIV KYUSHU NAT UNIV CORP (JP) 2020-04-01 — — EP disclosed
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2020-02-27 — — US disclosed
US-10406141-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2019-09-10 — — US disclosed
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2018-02-01 — — US disclosed
EP-3263133-A1 PYRIDINONE COMPOUND AND USE THEREOF Kyushu University, National University Corporation (JP) 2018-01-03 — — EP disclosed
WO-2016136985-A1 PYRIDINONE COMPOUND AND USE THEREOF 国立大学法人九州大学 2016-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 AKR1C3 341/4885AKR1C1 121/4885ALDH1A1 52/4885
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 AKR1C3 368/4885AKR1C1 126/4885ALDH1A1 49/4885
US-10406141-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 AKR1C3 341/4885AKR1C1 121/4885ALDH1A1 52/4885
US-11311523-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 AKR1C3 368/4885AKR1C1 126/4885ALDH1A1 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback